NASDAQ OMX

Merus Announces Third Quarter 2017 Financial Results and Clinical Highlights

Dela

UTRECHT, The Netherlands, Nov.  30, 2017  (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced financial results for the third quarter ended September 30, 2017 and provided a clinical update.

"Merus continues to make meaningful advances with both our proprietary pipeline, led by MCLA-128, and our various collaboration programs," said Ton Logtenberg, Ph.D., Chief Executive Officer of Merus. "We look forward to several milestones over the balance of the year, including our plan to initiate a Phase 2 clinical trial of MCLA-128 in combination with other therapies in HER2 positive and ER+/HER2 low metastatic breast cancer and plan to file a Clinical Trial Application ("CTA") for a first-in-human clinical trial of MCLA-158 in patients with colorectal cancer. Our Phase 1/2 clinical trial evaluating single agent activity for MCLA-128 in gastric, ovarian, endometrial and non-small cell lung (NSCL) cancers is ongoing and we anticipate defining the clinical plan for MCLA-128 for additional solid tumors in early 2018. Also in 2018, we intend to continue to advance MCLA-117 in the clinic for acute myeloid leukemia (AML) and progress MCLA-145, being developed in collaboration with Incyte."

"We are committed to unlocking the full potential of our Biclonics®-based bispecific antibody platform, and we anticipate 2018 will be an important year for advancing multiple programs in the clinic," added Dr. Logtenberg.

Upcoming Milestones

MCLA-128, an enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) Biclonics ® that binds to HER2 and HER3-expressing solid tumor cells

Merus intends to initiate a Phase 2 clinical trial of MCLA-128 in combination with other therapies in HER2 positive and ER+/HER2 low metastatic breast cancer by the end of 2017. In early 2018, Merus expects to formulate its clinical development plans in gastric, ovarian, endometrial and NSCL cancers based on a data readout from its ongoing Phase 1/2 clinical trial.

MCLA-117, a Biclonics ® that binds to CD3 and CLEC12A

Merus is continuing its dose escalation of the Phase 1 clinical trial for MCLA-117 in Europe, and expects to submit an Investigational New Drug application to the U.S. Food and Drug Administration in the first half of 2018.

MCLA-158, an ADCC-enhanced Biclonics ® designed to bind to cancer stem cells expressing Lgr5 and EGFR

Merus expects to file a CTA for a first-in-human clinical trial of MCLA-158 in patients with colorectal cancer by the end of 2017.

MCLA-145, a Biclonics ® designed to bind to PD-L1 and a second non-disclosed immunomodulatory target

Merus and Incyte are conducting an IND-enabling study for MCLA-145, the first drug candidate co-developed under their global research collaboration. Merus has full rights to develop and commercialize MCLA-145 in the United States and Incyte is responsible for its development and commercialization outside the United States.

Third Quarter 2017 Financial Results

Merus ended the third quarter of 2017 with cash and cash equivalents of €202.4 million compared to €56.9 million at December 31, 2016.

Total revenue for the three months ended September 30, 2017 was €3.5 million compared to €1.2 million for the same period in 2016. Revenue is comprised primarily of cost reimbursements, amortization of the Incyte upfront license payment, research funding and income from grants on research projects.

Research and development costs for the three months ended September 30, 2017 were €8.0 million compared to €4.1 million for the same period in 2016. The increase in research and development costs reflects higher enrollment in our clinical trials and expansion of research efforts to support our internal programs and collaboration with Incyte.

For the three months ended September 30, 2017, Merus reported a net loss of €15.7 million, or a loss of €0.81 per basic and diluted share, compared to a net loss of €4.9 million, or a loss of €0.31 per basic and diluted share, for the same period in 2016. The net loss for the three months ended September 30, 2017 includes approximately €5.5 million of foreign currency losses and approximately €2.7 million of non-cash, share option expenses.

Financial Outlook

Based on current operating plans, Merus expects that its current cash and cash equivalents balance will be sufficient to fund its research and development programs and operations well into 2019.

About Merus N.V.

Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have similar features as conventional monoclonal antibodies, such as long half-life and low immunogenicity. Merus' most advanced bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 2 combination trial in two metastatic breast cancer populations. MCLA-128 is also being evaluated in a Phase 1/2 clinical trial in Europe in gastric, ovarian, endometrial and non-small cell lung cancers. Merus' second most advanced bispecific antibody candidate, MCLA-117, is being developed in a Phase 1 clinical trial in patients with acute myeloid leukemia. The Company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, as well as MCLA-145, which is designed to bind to PD-L1 and a non-disclosed second immunomodulatory target and is being developed in collaboration with Incyte Corporation. For additional information, please visit Merus' website, www.merus.nl.

Forward Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the timing of initiating the Phase 2 combination clinical trial of MCLA-128 and defining the clinical development plan for MCLA-128 in additional solid tumors, clinical development plans for MCLA-117, the timing of filing a Clinical Trial Application for MCLA-158 for a clinical trial in patients with colorectal cancer, the progress of developing MCLA-145 with Incyte, 2018 being an important period for advancing multiple clinical programs, each statement under "Upcoming Milestones," and the sufficiency of our cash and cash equivalents.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our need for additional funding, which may not be available and which may require us to restrict our operations or require us to relinquish rights to our technologies or Biclonics® and bispecific antibody candidates; potential delays in regulatory approval, which would impact our ability to commercialize our product candidates and affect our ability to generate revenue; the lengthy and expensive process of clinical drug development, which has an uncertain outcome; the unpredictable nature of our early stage development efforts for marketable drugs; potential delays in enrollment of patients, which could affect the receipt of necessary regulatory approvals; our reliance on third parties to conduct our clinical trials and the potential for those third parties to not perform satisfactorily; we may not identify suitable Biclonics® or bispecific antibody candidates under our collaboration with Incyte or Incyte may fail to perform adequately under our collaboration; our reliance on third parties to manufacture our product candidates, which may delay, prevent or impair our development and commercialization efforts; protection of our proprietary technology; our patents may be found invalid, unenforceable, circumvented by competitors and our patent applications may be found not to comply with the rules and regulations of patentability; we may fail to prevail in existing and potential lawsuits for infringement of third-party intellectual property; and our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks.

These and other important factors discussed under the caption "Risk Factors" in our Annual Report on Form 20-F filed with the Securities and Exchange Commission, or SEC, on April 28, 2017, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except as required under applicable law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Merus N.V.
Unaudited Condensed Consolidated Statement of Financial Position
(after appropriation of result for the period)
 
     
  September 30,
2017
 
December 31,
2016  
  (euros in thousands)
Non-current assets    
Property, plant and equipment   1,008   648
Intangible assets   328   374
Restricted cash   -    167
Other assets   123   109
    1,459   1,298
     
Current assets    
Financial asset   -    11,847
Trade receivables and other current assets   4,062   2,248
Cash and cash equivalents   202,424   56,917
    206,486   71,012
Total assets   207,945   72,310
     
Shareholders' equity    
Issued and paid-in capital   1,747   1,448
Share premium account   213,551   139,878
Accumulated loss   (155,553)   (107,295)
Total equity   59,745   34,031
Non-current liabilities    
Borrowings   -    319
Deferred revenue, net of current portion   131,903   30,206
Current liabilities    
Borrowings   -    167
Trade payables   2,837   2,298
Taxes and social security liabilities   242   29
Deferred revenue   7,052   1,610
Other liabilities and accruals   6,166   3,650
    16,297   7,754
Total liabilities   148,200   38,279
Total equity and liabilities   207,945   72,310
     

 

Unaudited Condensed Consolidated Statement of Profit or Loss and Comprehensive Loss
 
         
  Three months ended
September 30,
 
Nine months ended
September 30,
 
  (euros in thousands, except per share data) 
  2017  2016  2017  2016 
Revenue   3,471    1,182    9,784    3,127 
Research and development costs   (8,040)   (4,074)   (23,075)   (11,924)
Management and administration costs   (3,634)   (546)   (11,432)   (1,560)
Other expenses   (2,180)   (1,522)   (6,588)   (4,977)
Total operating expenses   (13,854)   (6,142)   (41,095)   (18,461)
Operating result   (10,383)   (4,960)   (31,311)   (15,334)
Finance income   254    25    864    74 
Finance costs   (5,519)   (10)   (28,215)   (21)
Total finance (expense) / income   (5,265)   15    (27,351)   53 
Result before taxation   (15,648)   (4,945)   (58,662)   (15,281)
Income tax expense   (64)   -    (181)   - 
Result after taxation   (15,712)   (4,945)   (58,843)   (15,281)
Other comprehensive income        
Exchange differences on the translation of foreign operations   33    3    51    3 
Total other comprehensive income for the period   33    3    51    3 
Total comprehensive loss for the period   (15,679)   (4,942)   (58,792)   (15,278)
Basic (and diluted) loss per share   (0.81)   (0.31)   (3.08)   (1.24)
Weighted average shares outstanding        
Basic (and diluted)   19,402,667    16,085,851    19,120,081    12,293,405

Contacts:

Media:

Eliza Schleifstein
+1 973 361 1546
eliza@argotpartners.com

Investors:

Kimberly Minarovich
+1 646 368 8014
kimberly@argotpartners.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Merus N.V. via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

BIMobject AB: Correction: BIMobject among fastest growing tech companies in EMEA18.12.2017 15:47Pressmeddelande

BIMobject comes in at place 185 in an objective ranking of the 500 fastest growing tech companies in Europe, the Middle East, and Africa. In a corresponding ranking of Swedish companies, BIMobject places 24 th out of 50.  The Deloitte Technology Fast 500(TM) EMEA programme is an objective industry ranking that compares and lists the fastest growing technology companies in Europe, the Middle East, and Africa during the past four years. The 2017 winners were selected based on percentage fiscal-year revenue growth from 2013 to 2016. The regional ranking Sweden Technology Fast 50 lists the fastest growing companies in the Swedish tech industry.  "Our places in the Deloitte rankings are great news proving that our expansion strategy works. The BIMobject Cloud is now the world's leading platform for digital building products. That's the kind of innovation that drives us while we keep working towards growth", says Stef

BIMobject AB: Rättelse: BIMobject bland de snabbast växande techbolagen i EMEA18.12.2017 15:47Pressmeddelande

BIMobject hamnar på plats 185 i objektiv rankning av de 500 snabbast växande techföretagen i Europa, Mellanöstern och Afrika. I motsvarande rankning av svenska företag tilldelas BIMobject plats 24 av 50.  Programmet Deloitte Technology Fast 500(TM) EMEA är en objektiv branschrankning som jämför och listar de snabbast växande techföretagen i Europa, Mellanöstern och Afrika under de senaste fyra åren. Vinnarna för år 2017 valdes ut baserat på procentandelen inkomsttillväxt under räkenskapsåren 2013 till 2016. Den regionala rankningen Sweden Technology Fast 50 listar de snabbast växande företagen inom den svenska techbranschen.  "Våra placeringar i Deloittes rankningar är jätteroliga nyheter som visar att vår strategi för expansion håller. Molnlösningen BIMobject Cloud är nu världens ledande plattform för digitala byggobjekt. Det är sådan innovation vi drivs av samtidigt som vi fortsätter hålla siktet inställt på tillväxt", säger Stefan Larsson, VD och gru

BIMobject AB: BIMobject bland de snabbast växande techbolagen i EMEA18.12.2017 15:18Pressmeddelande

BIMobject hamnar på plats 158 i objektiv rankning av de 500 snabbast växande techföretagen i Europa, Mellanöstern och Afrika. I motsvarande rankning av svenska företag tilldelas BIMobject plats 24 av 50.  Programmet Deloitte Technology Fast 500(TM) EMEA är en objektiv branschrankning som jämför och listar de snabbast växande techföretagen i Europa, Mellanöstern och Afrika under de senaste fyra åren. Vinnarna för år 2017valdes ut baserat på procentandelen inkomsttillväxt under räkenskapsåren 2013 till 2016. Den regionala rankningen Sweden Technology Fast 50 listar de snabbast växande företagen inom den svenska techbranschen.  "Våra placeringar i Deloittes rankningar är jätteroliga nyheter som visar att vår strategi för expansion håller. Molnlösningen BIMobject Cloud är nu världens ledande plattform för digitala byggobjekt. Det är sådan innovation vi drivs av samtidigt som vi fortsätter hålla siktet inställt på tillväxt", säger Stefan Larsson, VD och grun

BIMobject AB: BIMobject among fastest growing tech companies in EMEA18.12.2017 15:18Pressmeddelande

BIMobject comes in at place 158 in an objective ranking of the 500 fastest growing tech companies in Europe, the Middle East, and Africa. In a corresponding ranking of Swedish companies, BIMobject places 24 th out of 50.  The Deloitte Technology Fast 500(TM) EMEA programme is an objective industry ranking that compares and lists the fastest growing technology companies in Europe, the Middle East, and Africa during the past four years. The 2017 winners were selected based on percentage fiscal-year revenue growth from 2013 to 2016. The regional ranking Sweden Technology Fast 50 lists the fastest growing companies in the Swedish tech industry.  "Our places in the Deloitte rankings are great news proving that our expansion strategy works. The BIMobject Cloud is now the world's leading platform for digital building products. That's the kind of innovation that drives us while we keep working towards growth", says Stef

SD-WAN Market Leader, Aryaka, Releases First EMEA Edition of its State of SD-WAN Connectivity Report18.12.2017 15:06Pressmeddelande

Research finds up to 20x cloud and SaaS application performance improvements when connecting via private network-based SD-WANs versus the public Internet LONDON, Dec. 18, 2017 (GLOBE NEWSWIRE) -- Aryaka®, the leading global SD-WAN provider, has released its first EMEA Edition of the State of SD-WAN Connectivity report that analyses the performance of SD-WAN deployments over the Internet as compared with those delivered over global private networks. The report highlights specific application response times between various European, Middle East, Asia-Pacific and Americas locations, as well as key factors that impact the performance of cloud and SaaS applications. This research helps IT leaders in Europe, Middle East and Africa (EMEA) to evaluate the best underlying connectivity for their SD-WAN deployments to ensure fast, reliable and consistent performance for all on-premises, cloud and SaaS applications, including voice, video, and data. The report reveals significant dif

Navigators to Acquire Belgian Specialty Insurer18.12.2017 07:30Pressmeddelande

STAMFORD, CT, December 18, 2017 - The Navigators Group, Inc. (NASDAQ:NAVG) today announced that it has entered into a share purchase agreement for the purchase of all of the shares of Assurances Continentales - Continentale Verzekeringen NV ("ASCO") and Bracht, Deckers & Mackelbert NV ("BDM").  ASCO and BDM are both based in Antwerp, Belgium. The proposed acquisition is part of Navigators' strategy of expanding its well-established specialty insurance expertise to more brokers and insureds across Europe. ASCO is a specialty insurance company offering marine and property and casualty insurance. BDM is an insurance underwriting agency that underwrites risk coverage in niche markets on behalf of ASCO and a number of major international insurers. Additionally, as part of the transaction, Navigators will acquire all the shares of Canal Re SA, a Luxembourg reinsurance company that is a wholly-owned subsidiary of ASCO.  The acquisition reinforces Navigators' presence in the European Un

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum